Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.
Hans C. Lee, MD
Advertisement
Articles by Hans C. Lee, MD
Hans C. Lee, MD, discusses updated data from the phase 2 LINKER-MM1 study evaluating linvoseltamab in patients with relapsed/refractory multiple myeloma.
Hans C. Lee, MD, discusses the investigation of the BCMA x CD3 bispecific antibody linvoseltamab in patients with relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Dr Lee on the Updated Efficacy and Safety Data for Linvoseltamab in R/R Multiple MyelomaPublished: January 9th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5